BNB Treasury Strategy Fails: Biotech Firm Windtree Loses 77% After Nasdaq Delisting

Windtree Therapeutics, a biotechnology company that adopted a BNB treasury strategy last month, experienced a significant market downturn after being delisted from the Nasdaq. The company was notified by the Nasdaq on Wednesday that it would be delisted for failing to meet compliance requirements regarding minimum share price ($1.00) outlined in Listing Rule 5550(a)(2). This triggered a suspension of trading for WINT stock, which dropped an astonishing 77% to $0.11. While the company’s BNB treasury strategy initially attracted some attention, it ultimately failed to provide protection against market volatility.